McIlrath & Eck’s MiMedx Group MDXG Stock Holding History

McIlrath & Eck’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$1K	–	563
2018 Q3	$1K	Hold	100	–	–	﹤0.01%	506
2018 Q2	$1K	Hold	100	–	–	﹤0.01%	490
2018 Q1	$1K	Hold	100	–	–	﹤0.01%	454
2017 Q4	$1K	Buy	+100	New	+$1.22K	﹤0.01%	491

Other funds holding MDXG

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TIM

Thompson Investment Management Madison, Wisconsin $872M AUM 35.59% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

WMC

Westwood Management Corporation Chicago, Illinois $270M AUM 54.59% 1-Year Est. Return

PAM

Pegasus Asset Management Montebello, New York $313M AUM 24.74% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

McIlrath & Eck's MDXG Position: Q4 2018 in Review

McIlrath & Eck sold out of MiMedx Group (MDXG) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

McIlrath & Eck first reported a position in MDXG in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 38 funds tracked by Wall St. Rank hold MDXG as of Q4 2018.

McIlrath & Eck reported no remaining MiMedx Group position as of Q4 2018 after selling out during the quarter.
McIlrath & Eck sold 100 MiMedx Group shares in Q4 2018, an estimated $1K.
McIlrath & Eck first reported a position in MiMedx Group in Q4 2017 and held it in 4 quarters.
McIlrath & Eck's MiMedx Group position peaked at $1K in Q3 2018.
38 funds tracked by Wall St. Rank held MiMedx Group as of Q4 2018.

Based on McIlrath & Eck's 13F filing for Q4 2018, filed 7 May 2019.